Eurofins creates one of the largest dedicated testing sites of its kind in the UK
£4 million investment will allow the Biopharmaceutical Product Testing business to expand its finished product and raw materials testing and increase capacity to deal with higher volumes.
Eurofins Scientific (EUFI.PA) has opened a new pharmaceutical chemistry and microbiology facility in Livingston, Scotland, following a £4 million investment.
The 5800-m2 facility will become one of the largest dedicated testing sites of its kind in the UK and the Biopharmaceutical Product Testing (BPT) UK business plans to double employee numbers over the next 5 years.
The new facility will allow the BPT business to expand its finished product and raw materials testing and increase capacity to deal with higher volumes. A greater number of technical specialists will also be available to work on method development and validation.
GMP microbiology contract testing will also be a focus, alongside elemental impurity testing which has benefited from the purchase of new equipment to enhance the capability of inductively coupled plasma mass spectrometry (ICP-MS) testing, enabling the company to meet growing demand for this service.
Eurofins will also invest in more high-performance liquid chromatography (HPLC) equipment, increasing its capacity by 40%.
Alison Clayton, General Manager, said the Livingston site would be one of the largest of all the Eurofins UK sites, which form part of a network of laboratories that work together across the UK, Ireland and Europe.
“The large investment in the facility will position the company in the best place to attract new customers thanks to greatly increased capacity, and is in line with Eurofins’ intent to attract significant future growth and development opportunities.
Eurofins BPT UK business will move from its current site in Newbridge, Edinburgh. The Livingston facility will also house new laboratories for Eurofins’ water testing business.
The investment follows Eurofins’ acquisition of Exova’s pharmaceutical, food and water testing business in the UK & Ireland in July 2016, and the subsequent purchase of ILS’s pharmaceutical business in October 2016.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...